Drug Type Small molecule drug |
Synonyms 4-Amino-N-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide, Cidine, Cinigest + [7] |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT1B receptor agonists(Serotonin 1b (5-HT1b) receptor agonists), 5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date ES (16 Apr 2010), |
Regulation- |
Molecular FormulaC25H36N4O10 |
InChIKeyHVANMRCHFMTSEG-LREBCSMRSA-N |
CAS Registry96623-56-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07701 | Cinitapride Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyspepsia | ES | 16 Apr 2010 | |
Gastroesophageal Reflux | ES | 16 Apr 2010 |
Phase 3 | 383 | vzfuixefre(jcplstxuuj) = Cinitapride-related adverse events were observed in 9.1% of patients, including 1 patient with extrapyramidal symptoms ajgrdlxtup (yphbokaqvo ) View more | - | 01 Apr 2014 | |||